ClinicalTrials.gg
RecruitingNCT07574632RESILIENTUpdated Jun 1, 2026

A Study to Evaluate a New Semi-rigid Brace, the RESILIENT Brace by Thinks Works, as a Way to Limit Curve Worsening in Kids With Idiopathic Scoliosis.

An interventional study of The RESILIENT scoliosis brace system in Idiopathic Scoliosis, sponsored by Thinks Works, PBC. Recruiting at 1 site in United States. Open to participants aged 9 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Thinks Works, PBC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
9 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Scoliosis with a site in United States — 42 open to participants now, 51 under way, 2 of them phase 3. Scoliosis · United States.

Planned enrollment
63rd of 91
30 · median 58
Started
2026
with 4 others
No phase
65 of 153
16 open now
Primary completion
2029-05
later than 42 of 50 live
Registered
148th of 153
by date

Among the 153 studies in Scoliosis with a site in United States, this one is the 63rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2026, is one of 65 with no phase, reaches primary completion later than 42 of the 50 other live ones, and was the 148th registered.

Scoliosis

660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.

Browse Scoliosis studies →

Open to participants now

42 of the 153 studies in Scoliosis with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.

This study: 9 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Scoliosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the RESILIENT Scoliosis Brace System works to treat children with idiopathic scoliosis. It will also learn about the safety, comfort, and usability of the brace. The main questions it aims to answer are:

  • Can the RESILIENT brace prevent the spinal curve from progressing beyond 35 degrees during growth?
  • How much does the brace correct the curve when it is first worn (in-brace correction)?
  • How well do participants follow the prescribed brace wear time and force levels?
  • How does wearing the brace affect quality of life and daily activities?

Researchers will study a single group of participants using the RESILIENT brace and evaluate outcomes over time using standard clinical assessments, including X-rays and patient-reported questionnaires.

Participants will:

  • Be fitted with the RESILIENT brace and instructed on how to use it
  • Wear the brace daily according to physician recommendations throughout their growth period
  • Attend clinic visits at approximately 4-6 weeks after starting treatment and then about every 6 months for follow-up evaluations
  • Undergo standard-of-care spine X-rays to monitor curve progression
  • Complete questionnaires about their quality of life and experience with the brace
  • Have brace wear time and applied forces monitored using sensors embedded in the device

Participants will be followed from the start of brace treatment until they are done growing and have completed treatment.

03

Conditions studied

  • Idiopathic Scoliosis

Browse trials for

Keywords

  • scoliosis
  • brace
  • idiopathic scoliosis
  • flexible brace
  • semi-rigid brace
  • adolescent idiopathic scoliosis
  • AIS
  • IS
04

Who can participate

Ages eligible
9 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Idiopathic Scoliosis (IS)
  • Age of 9 - 16 years when brace treatment is prescribed
  • Primary right apex main thoracic scoliosis curve with an apex of T6 or lower
  • Cobb angle, as measured on a standing PA spine x-ray, 20 degrees or larger and 30 degrees or less, obtained no more than 6 weeks prior to trial enrollment.
  • Sanders Skeletal Maturity Score of 1-5
  • No prior brace treatment or surgery for scoliosis
  • Patient \& guardian select the RESILIENT brace for treatment
  • The guardian must confirm that there is cellular connectivity at the place(s) where the patient lives

Exclusion criteria

Exclusion Criteria:

  • Scoliosis other than idiopathic scoliosis: e.g. Neuromuscular, Congenital, or Syndrome Related
  • Age less than 9 years or older than 16 years
  • Sanders Skeletal Maturity Score of 6 or greater
  • Primary Left apex thoracic scoliosis
  • Primary lumbar scoliosis
  • Primary Right Thoracic curve with an apex above T6
  • Inability to remove and apply the brace independently
  • Inability to respond to written and verbal questions
  • Patient \& Guardian select traditional TLSO for treatment
  • Guardian confirms there is no cellular connectivity at the place(s) where the patient lives
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    RESILIENT Scoliosis Brace System

    Patients will be fitted with a novel semi-rigid, low-profile, adjustable, and modular scoliosis brace with embedded sensors measuring force and wear time.

    Device: The RESILIENT scoliosis brace system

Interventions

  • DeviceThe RESILIENT scoliosis brace system

    The RESILIENT brace is a novel semi-rigid (flexible), concealable, adjustable and modular brace with embedded sensors measuring force and wear time.

    Also known as: The RESILIENT brace

06

What researchers measure

Primary outcomes

  1. Treatment Success Based on Curve Progression at Skeletal Maturity

    Treatment success is defined as a right main thoracic Cobb angle less than or equal to 35 degrees at skeletal maturity. Treatment failure is defined as progression of the curve to greater than 35 degrees at any time during the treatment period. Cobb angle measurements are obtained from standing posteroanterior spine radiographs and assessed by independent reviewers blinded to patient information. Skeletal maturity is defined as a Sanders Skeletal Maturity Score of ≥7B, absence of longitudinal height increase over the preceding 6 months, and, for female participants, at least 18 months post-menarche.

    Time frame: From baseline to skeletal maturity (approximately up to 36 months)

Secondary outcomes

  1. In-Brace Curve Correction at Initial Follow-up

    Percent reduction in the primary right main thoracic Cobb angle on standing in-brace posteroanterior spine radiographs obtained at the 4- to 6-week follow-up visit, compared with baseline standing radiographs obtained prior to brace treatment.

    Time frame: 4 to 6 weeks

  2. Measurement of brace use compliance as a percentage of prescribed use.

    Percent compliance with prescribed daily brace wear time and prescribed apex strap force, as measured by force sensors integrated into the brace and recorded in the monitoring system.

    Time frame: From brace initiation through completion of treatment, approximately up to 36 months

  3. Change in Curve Magnitude Following Completion of Brace Treatment

    Percent change in the primary right main thoracic Cobb angle from baseline to the final follow-up radiograph obtained after brace discontinuation.

    Time frame: From baseline to 4 to 6 months after brace discontinuation

  4. PROMIS Pediatric Quality of Life Scores

    Patient-reported outcomes measured using PROMIS pediatric modules. Theses are rated using a numeric rating scale. Physical function-mobility is scored 1-4 with 4 being the best outcome score. Peer relationships is scored 1-5 with 5 being the best outcome score. Depressive symptoms is scored 1-5 with 1 being the best outcome score.

    Time frame: Baseline and longitudinal follow-up visits throughout the study, approximately up to 36 months

  5. Scoliosis Research Society-22 (SRS-22) Score

    Patient-reported scoliosis-related quality of life measured using the SRS-22 questionnaire.

    Time frame: Baseline and longitudinal follow-up visits throughout the study, approximately up to 36 months

  6. Patient and Parent Clinical Trial Completion Exit Survey

    When the patient has completed the clinical trial the patient and parent(s)/guardians will be given a survey to assess their overall experience with the brace treatment. It has questions with numerical rating scores from 1-5 with 1 being the best outcome score and questions with descriptive ratings from very positive-very negative, strongly agree-strongly disagree, very likely-very unlikely, extremely willing-not willing.

    Time frame: This survey will be given to patients at the completion of their participation in the study, approximately 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 234 interventional studies with no phase under Scoliosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 60. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2026
First posted
May 8, 2026
StartActual
May 28, 2026
Primary completionEst.
May 2029
CompletionEst.
Aug 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07574632
Lead sponsor
Thinks Works, PBC
Collaborators
Setting Scoliosis Straight Foundation, Nemours Children's Hospital
Responsible party
Sponsor
First posted
May 8, 2026
Start date
May 28, 2026
Primary completion
May 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Avery Patient Experience Liaison, Thinks Works
Contact
hello@thinksworks.com
844-542-7374
Ryan C. Murdock, MD, MS. CEO of Thinks Works.
Contact
info@thinksworks.com
Suken A. Shah, MD
principal investigator · Nemours Hospital for Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion